儿童慢性免疫性血小板减少症患者的血小板生成素受体激动剂逐渐减量：是否可行？

Tapering of the thrombopoietin receptor agonist in paediatric patients with chronic immune thrombocytopenia: Is it possible?

机构信息

Servicio de Hematología Pediátrica, Hospital Sant Joan de Déu, Barcelona, Spain.

Grupo trabajo de la PTI de la Sociedad Española de Hematología y Oncología Pediátricas.

出版信息

Br J Clin Pharmacol. 2022 Sep;88(9):4220-4223. doi: 10.1111/bcp.15378. Epub 2022 May 12.

DOI:10.1111/bcp.15378

PMID:35491467

Abstract

It is not clear if platelet responses are sustained after thrombopoietin receptor agonist (ar-TPO) withdrawal in paediatric patients. A multicentre retrospective observational study was performed in children with chronic immune thrombopenia (cITP) to describe ar-TPO tapering and withdrawal in patients who had achieved a sustained complete response to ar-TPOs. Ten patients (eltrombopag n = 6, romiplostim n = 4) were included. Treatment withdrawal was performed after a mean tapering time of 7.6 months. Two patients relapsed (median follow-up time of 24 months). Slow tapering and withdrawal of ar-TPOs can be safely performed in cITP paediatric patients after achieving a sustained complete response.

摘要

尚不清楚在儿科患者停用促血小板生成素受体激动剂（ar-TPO）后，血小板反应是否持续。对患有慢性免疫性血小板减少症（cITP）的儿童进行了一项多中心回顾性观察研究，以描述在对 ar-TPO 获得持续完全反应的患者中逐渐减少和停用 ar-TPO。纳入了 10 名患者（eltrombopag n = 6，romiplostim n = 4）。在平均 7.6 个月的逐渐减量时间后，停止了治疗。两名患者复发（中位随访时间为 24 个月）。在获得持续完全缓解后，cITP 儿科患者可安全地逐渐减少和停用 ar-TPO。